Healthcare products
Child Health
Deficiency States and Supplementation
Dermatological Health
Pain treatment
Gastrointestinal Health
Genitourinary Health
Cardiorespiratory Health
Corticotherapy
Oral-Pharyngeal Health
Fluid Therapy
CNS Treatment
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu.
This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health, supporting projects that contribute to the advancement of medical knowledge and to improving care for children with complex conditions.
Sant Joan de Déu is one of Europe’s leading highly specialized pediatric centers and a benchmark in research, particularly in the treatment of complex and rare diseases. Currently, the hospital cares for more than 28,000 patients with rare diseases, conditions that in 70% of cases manifest during childhood and for which only 6% have a specific treatment.
Through this initiative, Laboratorios ERN reaffirms its commitment to pediatric research and to those areas with the greatest medical and social need.
More defenses for them. More energy for research.
noticias relacionadas
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability. This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the […]
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu. This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health, supporting projects that contribute […]
Ernamín at the 55th Congress of the Spanish Society of Nephrology
From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo. For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level […]
Incremental Drug Innovation: A Priority Focus for Laboratorios ERN
David Solanes López, General Manager of Laboratorios ERN, was appointed Academician of the Royal Academy of Pharmacy of Catalonia on October 6, 2025, in the industrial section. Solanes dedicated his induction speech to incremental innovation, an area closely linked to his professional career and to Laboratorios ERN’s commitment to developing solutions that improve patients’ lives. […]
FDA has approved intravenous fosfomycin for the treatment of cUTI
On October 22, 2025, the U.S. Food and Drug Administration (FDA) approved intravenous fosfomycin for the treatment of complicated urinary tract infections (cUTI). Laboratorios ERN expresses its satisfaction with the recent approval by the U.S. Food and Drug Administration (FDA) of intravenous fosfomycin for the treatment of patients aged 18 years and older with complicated […]